In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich.
Blog |
23 March 2021

5 things we learned in taking on big pharma

INTELLECTUAL PROPERTY AND TRADE
Photograph by Peter Bauza
In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich. Photograph by Peter Bauza
https://msf-access.medium.com/5-things-we-learned-in-taking-on-big-pharma-5ade49bd325a?source=friends_link&sk=256bed2f5277c75cbee096d7b41bbc80

For over ten years, I have been working with inspiring teams around the globe creating and coordinating public campaigns that ignite people’s imaginations and change lives. Here are five things I learned.